Experimental Vaccine Shows Promise In Preventing Active TB Disease Among Those With Latent Infection, Researchers Say
Associated Press: Vaccine shows promise for preventing active TB disease
“An experimental vaccine proved 50% effective at preventing latent tuberculosis infection from turning into active disease in a three-year study of adults in Africa. … Results were reported Tuesday at a conference in India, the country hardest hit by TB, and published by the New England Journal of Medicine…” (Marchione, 10/29).
BBC News: ‘Game changing’ tuberculosis vaccine a step closer
“…The team of researchers, who come from all over the world, revealed the vaccine, which is made up of proteins from bacteria which trigger an immune response, during a global summit on lung health in the southern Indian city of Hyderabad on Tuesday. It has already cleared a critical phase of clinical trials and been tested on more than 3,500 adults in TB endemic regions of South Africa, Kenya and Zambia, researchers said…” (Biswas, 10/29).
New York Times: New TB Vaccine Could Save Millions of Lives, Study Suggests
“…The new vaccine, made by GSK and now known as M72/AS01E, was tested in about 3,300 adults in Kenya, South Africa and Zambia. All of them already had latent tuberculosis — a silent infection that might or might not progress to active tuberculosis. Of those who got two doses of the GSK vaccine, only 13 developed active tuberculosis during three years of follow-up, according to the new study published in the New England Journal of Medicine. By contrast, 26 of those who got a placebo progressed to active tuberculosis…” (McNeil, 10/29).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.